Loading…

Neuroendocrine bladder cancer: oncological emergency?

Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history. However, prognosis is usually poor and the survival rate at 5 years does not exceed...

Full description

Saved in:
Bibliographic Details
Published in:Urologia 2008-01, Vol.75 (1), p.57-61
Main Authors: Fiorito, C, Lucca, I, Oderda, M, Mondino, P, Berta, G, Cattaneo, E A, Valentino, F, Zitella, A, Pacchioni, D
Format: Article
Language:Italian
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3
cites cdi_FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3
container_end_page 61
container_issue 1
container_start_page 57
container_title Urologia
container_volume 75
creator Fiorito, C
Lucca, I
Oderda, M
Mondino, P
Berta, G
Cattaneo, E A
Valentino, F
Zitella, A
Pacchioni, D
description Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history. However, prognosis is usually poor and the survival rate at 5 years does not exceed 8%, if untreated. METHODS. We are here describing three case reports of bladder carcinoma with neuroendocrine differentiation, which is extremely aggressive and leads rapidly to death. At the present time, the local control of these tumors is achieved by radical cystectomy and radiotherapy; they can be both associated to chemotherapy. However, since these lesions are fairly rare, there is no gold standard therapy and there are no prospective studies on the management of these tumors. CONCLUSIONS. Considering the quick evolution and progression of any variant of the neuroendocrine tumors of the bladder, urologists and anesthetists should see them as real oncological emergencies. A prompt intervention through radical surgery with cystectomy and linfadenectomia, and the anathomo-pathologist's systematic investigation of the scraps could make the approach therapeutic and not only palliative. Prospective studies on neo-adjuvant chemotherapy as well as experimental studies about target therapies may yield new guidelines on the tumor management.
doi_str_mv 10.1177/039156030807500111
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727652944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1727652944</sourcerecordid><originalsourceid>FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3</originalsourceid><addsrcrecordid>eNplkD9PwzAUxC0EolHpF2BAGVkCz3ZsxywIVfyTKlhgjhz7pQpK4mI3Q789rlpYeMtJT7876Y6QSwo3lCp1C1xTIYFDBUoAUEpPSEYVKwuZHqck2wPFnpiRRYxfkE4CKxk_JzNGoZJcVRkRbzgFj6PzNnQj5k1vnMOQWzNaDHe5H63v_bqzps9xwLDG0e7uL8hZa_qIi6POyefT48fypVi9P78uH1aFZZxvC1u1gEaUSmLTqgpkBVUjtNMWUweKTFPmuDAMDWipdascSAoSFUsmhnxOrg-5m-C_J4zbeuiixb43I_op1qmvkoLpskwoO6A2-BgDtvUmdIMJu5pCvV-s_r9YMl0d86dmQPdn-d2H_wDr0GOy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1727652944</pqid></control><display><type>article</type><title>Neuroendocrine bladder cancer: oncological emergency?</title><source>Sage Journals Online</source><creator>Fiorito, C ; Lucca, I ; Oderda, M ; Mondino, P ; Berta, G ; Cattaneo, E A ; Valentino, F ; Zitella, A ; Pacchioni, D</creator><creatorcontrib>Fiorito, C ; Lucca, I ; Oderda, M ; Mondino, P ; Berta, G ; Cattaneo, E A ; Valentino, F ; Zitella, A ; Pacchioni, D</creatorcontrib><description>Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history. However, prognosis is usually poor and the survival rate at 5 years does not exceed 8%, if untreated. METHODS. We are here describing three case reports of bladder carcinoma with neuroendocrine differentiation, which is extremely aggressive and leads rapidly to death. At the present time, the local control of these tumors is achieved by radical cystectomy and radiotherapy; they can be both associated to chemotherapy. However, since these lesions are fairly rare, there is no gold standard therapy and there are no prospective studies on the management of these tumors. CONCLUSIONS. Considering the quick evolution and progression of any variant of the neuroendocrine tumors of the bladder, urologists and anesthetists should see them as real oncological emergencies. A prompt intervention through radical surgery with cystectomy and linfadenectomia, and the anathomo-pathologist's systematic investigation of the scraps could make the approach therapeutic and not only palliative. Prospective studies on neo-adjuvant chemotherapy as well as experimental studies about target therapies may yield new guidelines on the tumor management.</description><identifier>ISSN: 0391-5603</identifier><identifier>EISSN: 1724-6075</identifier><identifier>DOI: 10.1177/039156030807500111</identifier><identifier>PMID: 21086378</identifier><language>ita</language><publisher>United States</publisher><ispartof>Urologia, 2008-01, Vol.75 (1), p.57-61</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3</citedby><cites>FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21086378$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fiorito, C</creatorcontrib><creatorcontrib>Lucca, I</creatorcontrib><creatorcontrib>Oderda, M</creatorcontrib><creatorcontrib>Mondino, P</creatorcontrib><creatorcontrib>Berta, G</creatorcontrib><creatorcontrib>Cattaneo, E A</creatorcontrib><creatorcontrib>Valentino, F</creatorcontrib><creatorcontrib>Zitella, A</creatorcontrib><creatorcontrib>Pacchioni, D</creatorcontrib><title>Neuroendocrine bladder cancer: oncological emergency?</title><title>Urologia</title><addtitle>Urologia</addtitle><description>Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history. However, prognosis is usually poor and the survival rate at 5 years does not exceed 8%, if untreated. METHODS. We are here describing three case reports of bladder carcinoma with neuroendocrine differentiation, which is extremely aggressive and leads rapidly to death. At the present time, the local control of these tumors is achieved by radical cystectomy and radiotherapy; they can be both associated to chemotherapy. However, since these lesions are fairly rare, there is no gold standard therapy and there are no prospective studies on the management of these tumors. CONCLUSIONS. Considering the quick evolution and progression of any variant of the neuroendocrine tumors of the bladder, urologists and anesthetists should see them as real oncological emergencies. A prompt intervention through radical surgery with cystectomy and linfadenectomia, and the anathomo-pathologist's systematic investigation of the scraps could make the approach therapeutic and not only palliative. Prospective studies on neo-adjuvant chemotherapy as well as experimental studies about target therapies may yield new guidelines on the tumor management.</description><issn>0391-5603</issn><issn>1724-6075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNplkD9PwzAUxC0EolHpF2BAGVkCz3ZsxywIVfyTKlhgjhz7pQpK4mI3Q789rlpYeMtJT7876Y6QSwo3lCp1C1xTIYFDBUoAUEpPSEYVKwuZHqck2wPFnpiRRYxfkE4CKxk_JzNGoZJcVRkRbzgFj6PzNnQj5k1vnMOQWzNaDHe5H63v_bqzps9xwLDG0e7uL8hZa_qIi6POyefT48fypVi9P78uH1aFZZxvC1u1gEaUSmLTqgpkBVUjtNMWUweKTFPmuDAMDWipdascSAoSFUsmhnxOrg-5m-C_J4zbeuiixb43I_op1qmvkoLpskwoO6A2-BgDtvUmdIMJu5pCvV-s_r9YMl0d86dmQPdn-d2H_wDr0GOy</recordid><startdate>200801</startdate><enddate>200801</enddate><creator>Fiorito, C</creator><creator>Lucca, I</creator><creator>Oderda, M</creator><creator>Mondino, P</creator><creator>Berta, G</creator><creator>Cattaneo, E A</creator><creator>Valentino, F</creator><creator>Zitella, A</creator><creator>Pacchioni, D</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200801</creationdate><title>Neuroendocrine bladder cancer: oncological emergency?</title><author>Fiorito, C ; Lucca, I ; Oderda, M ; Mondino, P ; Berta, G ; Cattaneo, E A ; Valentino, F ; Zitella, A ; Pacchioni, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ita</language><creationdate>2008</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fiorito, C</creatorcontrib><creatorcontrib>Lucca, I</creatorcontrib><creatorcontrib>Oderda, M</creatorcontrib><creatorcontrib>Mondino, P</creatorcontrib><creatorcontrib>Berta, G</creatorcontrib><creatorcontrib>Cattaneo, E A</creatorcontrib><creatorcontrib>Valentino, F</creatorcontrib><creatorcontrib>Zitella, A</creatorcontrib><creatorcontrib>Pacchioni, D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fiorito, C</au><au>Lucca, I</au><au>Oderda, M</au><au>Mondino, P</au><au>Berta, G</au><au>Cattaneo, E A</au><au>Valentino, F</au><au>Zitella, A</au><au>Pacchioni, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroendocrine bladder cancer: oncological emergency?</atitle><jtitle>Urologia</jtitle><addtitle>Urologia</addtitle><date>2008-01</date><risdate>2008</risdate><volume>75</volume><issue>1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>0391-5603</issn><eissn>1724-6075</eissn><abstract>Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history. However, prognosis is usually poor and the survival rate at 5 years does not exceed 8%, if untreated. METHODS. We are here describing three case reports of bladder carcinoma with neuroendocrine differentiation, which is extremely aggressive and leads rapidly to death. At the present time, the local control of these tumors is achieved by radical cystectomy and radiotherapy; they can be both associated to chemotherapy. However, since these lesions are fairly rare, there is no gold standard therapy and there are no prospective studies on the management of these tumors. CONCLUSIONS. Considering the quick evolution and progression of any variant of the neuroendocrine tumors of the bladder, urologists and anesthetists should see them as real oncological emergencies. A prompt intervention through radical surgery with cystectomy and linfadenectomia, and the anathomo-pathologist's systematic investigation of the scraps could make the approach therapeutic and not only palliative. Prospective studies on neo-adjuvant chemotherapy as well as experimental studies about target therapies may yield new guidelines on the tumor management.</abstract><cop>United States</cop><pmid>21086378</pmid><doi>10.1177/039156030807500111</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0391-5603
ispartof Urologia, 2008-01, Vol.75 (1), p.57-61
issn 0391-5603
1724-6075
language ita
recordid cdi_proquest_miscellaneous_1727652944
source Sage Journals Online
title Neuroendocrine bladder cancer: oncological emergency?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T14%3A59%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroendocrine%20bladder%20cancer:%20oncological%20emergency?&rft.jtitle=Urologia&rft.au=Fiorito,%20C&rft.date=2008-01&rft.volume=75&rft.issue=1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=0391-5603&rft.eissn=1724-6075&rft_id=info:doi/10.1177/039156030807500111&rft_dat=%3Cproquest_cross%3E1727652944%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c233t-c8f0ea5476ebf7806808b59d9ce1171e2912d35a2ea09699f7d06106e725472e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1727652944&rft_id=info:pmid/21086378&rfr_iscdi=true